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AbstrACt
Objective Gestational diabetes is the most common 
metabolic disorder of pregnancy, and it is important 
that well-written clinical practice guidelines (CPGs) 
are used to optimise healthcare delivery and improve 
patient outcomes. The aim of the study was to assess 
the methodological quality of hospital-based CPGs on the 
identification and management of gestational diabetes.
Design We conducted an assessment of local clinical 
guidelines in English for gestational diabetes using the 
Appraisal of Guidelines for Research and Evaluation 
(AGREE II) to assess and validate methodological quality.
Data sources and eligibility criteria We sought a 
representative selection of local CPGs accessible by the 
internet. Criteria for inclusion were (1) identified as a 
guideline, (2) written in English, (3) produced by or for 
the hospital in a Western country, (4) included diagnostic 
criteria and recommendations concerning gestational 
diabetes, (5) grounded on evidence-based medicine and 
(6) accessible over the internet. No more than two CPGs 
were selected from any single country.
results Of the 56 CPGs identified, 7 were evaluated 
in detail by five reviewers using the standard AGREE II 
instrument. Interrater variance was calculated, with strong 
agreement observed for those protocols considered by 
reviewers as the highest and lowest scoring based on 
the instrument. CPG results for each of the six AGREE II 
domains are presented categorically using a 5-point Likert 
scale. Only one CPG scored above average in five or more 
of the domains. Overall scores ranged from 91.6 (the 
strongest) to 50 (the weakest). Significant variation existed 
in the methodological quality of CPGs, even though they 
followed the guideline of an advising body. Specifically, 
appropriate identification of the evidence relied on to 
inform clinical decision making in CPGs was poor, as 
was evidence of user involvement in the development of 
the guideline, resource implications, documentation of 
competing interests of the guideline development group 
and evidence of external review.
Conclusions The limitations described are important 
considerations for updating current and new CPGs.
IntrODuCtIOn
Diabetes, the most common metabolic 
disorder of pregnancy, carries multiple 
risks for both mother and baby.1 2 Diabetes 
in pregnancy may be classified into pre-ex-
isting type 1 Diabetes, type 2 diabetes and 
gestational diabetes mellitus (GDM). GDM is 
defined by hyperglycaemia with onset or first 
recognition during pregnancy.3 4 Between 
40% and 60% of women diagnosed with GDM 
go on to develop type 2 diabetes in later life 
and are significantly more likely to require a 
caesarean delivery. Evidence suggests babies 
of diabetic mothers have an increased risk 
of childhood obesity and diabetes. The use 
of evidence-based guidelines for the preven-
tion and treatment of GDM can reduce the 
adverse outcomes in pregnancy and child-
hood. The aim of the study was to assess the 
methodological quality of local clinical prac-
tice guidelines (CPGs) on the identification 
and management of GDM.
Gestational diabetes mellitus
GDM occurs in 2%–25% of pregnancies5 6 and, 
depending on the diagnostic criteria used, 
rates in the UK may be as high as 17%.6 7 While 
the original definition for GDM was based on 
maternal risk for developing diabetes post-
partum,8 newer glucose criteria have been 
developed based on risk of maternal and 
neonatal complications.8 9 While there have 
been five international workshops devoted to 
strengths and limitations of this study
 ► Evaluation of each guideline by five reviewers.
 ► Comparative analysis of hospital-based guidelines.
 ► Use of an accepted, structured and validated tool.
 ► Inclusion of English-language only guidelines 
and exclusion of those published prior to 2013 
mean those from non-English-speaking countries 
and some older well-known guidelines were not 
assessed.
 ► Use of a  categorical rather than a  statistical pre-
sentation of intra-domain results means that while 
results are more approachable, individual reviewer 
scores are not shown.
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GDM,10 the diagnostic criteria for GDM remain an area of 
considerable debate.11 The Hyperglycaemia and Adverse 
Pregnancy Outcomes (HAPO) study demonstrated 
a linear association between increasing levels of maternal 
hyperglycaemia and adverse perinatal outcomes, with 
no obvious threshold.1 Diagnostic criteria based on the 
HAPO study were proposed by the International Associa-
tion of Diabetes in Pregnancy Study Group (IADPSG) in 
2010.8 Their guidelines present diagnostic plasma glucose 
levels for before (fasting), and at 1 and 2 hours after 
administration of an oral 75 g glucose load that identify 
patients whose babies have nearly double the risk of three 
specific adverse clinical outcomes: macrosomia, increased 
adiposity and hypoglycaemia.8 These diagnostic criteria 
have been subsequently adopted by the WHO, Canadian 
Diabetes Association (CDA)12 and Australian Diabetes 
in Pregnancy Society (ADIPS).13 However, they remain 
controversial and have not been supported by other 
bodies, and there has been no randomised control trial 
to test the efficacy of these criteria.14 Furthermore, WHO 
have acknowledged they must be revisited in light of weak 
support for their diagnostic criteria, and newer studies 
on cost-effectiveness.15 The same reasons were also cited 
by New Zealand’s Best Practice Advocacy Centre (BPAC) 
when they persisted in using older, better supported diag-
nostic criteria.16 In 2015 National Institute for Health and 
Care Excellence (NICE) published an updated guidance 
on diabetes in pregnancy that included recommenda-
tions on diagnostic thresholds for GDM that differ from 
those adopted by WHO.14 Recent analysis suggests NICE 
thresholds are more cost effective than those of WHO, 
but this may be applicable only within the UK setting.17 
Table 1 summarises a comparison of screening and diag-
nostic criteria for diagnosing GDM as referenced or relied 
on by the CPGs in this study.
Clinical practice guidelines
Reliance on the best evidence is fundamental to ensuring 
quality healthcare. Valid guidelines for clinical practice 
are a powerful tool and the key to informing evidence-
based practice.18 19 The Institute of Medicine defines CPGs 
as statements that include recommendations, intended to 
optimise patient care, informed by a systematic review of 
evidence and an assessment of the benefits and harms 
of alternative care options.20 CPGs are underpinned by 
systematic review of evidence and are usually formulated 
by groups of stakeholders with relevant domain expertise. 
They may be developed at local, national and interna-
tional levels, and International CPGs are often adopted 
nationally or locally, although with local clinical and 
demographic setting-specific alterations.21 CPGs repre-
sent a convenient method for evaluating and assimilating 
evidence and presenting standardised recommendations 
to those tasked with delivering healthcare.19
Primary goals of CPGs are reductions in both variation 
in clinical practice and the expense of repeating inap-
propriate treatments.22 23 Achieving this goal is said to 
improve the quality of care received by patients, while 
reducing the incidence of inappropriate treatment.23 24 In 
2008, the UK NICE systematically reviewed the evidence 
for effectiveness for various interventions to manage all 
types of diabetes during pregnancy including GDM. This 
review led to publication of a complete preconception to 
postnatal diabetes in pregnancy management guideline,25 
updated with more recent evidence and recommenda-
tions in 2015.14 Others, such as New Zealand’s BPAC, act 
as little more than localised extensions of NICE, even 
affording NICE oversight of all guideline adaptation 
efforts.26 Such approaches may limit beneficial innova-
tion of clinical practices, application to the local popu-
lation and, when a particular guideline is found wanting, 
blind adherence may even increase potential harm and 
spread it over a significantly larger patient population.27 28
Since 2017, the authors have been involved in a research 
project (PAMBAYESIAN) to create a new generation of 
easy-to-use medical decision support systems for direct 
patient and clinician use.29 One of the project’s case 
Table 1 Comparison of screening and diagnostic criteria of gestational diabetes
Year Patient screening
Two-
step 
testing Screening
Screening 
threshold
OGTT 
glucose 
load (g)
Dx thresholds
(BGL in mmol/L)
Elevated 
OGTT values 
for DxFBG 1 hour 2 hour
NICE 2015 Clinical risk 75 5.6 - 7.8 1
SIGN 2017 Clinical risk 75 5.1 10 8.5 1
BPAC 2014 All Y 50 g GCT 7.8 75 5.5 - 9.0 1
CDA 2013 All Y 50 g GCT 7.8 75 5.3 10.6 9.0 1
IADPSG 2010 All 75 5.1 10.0 8.5 1
ADIPS 2014 All, unless 
resources limited
75 5.1 10.0 8.5 1
WHO 2013 All 75 5.1 10.0 8.5 1
ADIPS, Australian Diabetes in Pregnancy Society; BPAC, Best Practice Advocacy Group New Zealand; CDA, Canadian Diabetes 
Association; FBG, fasting blood glucose; GCT, glucose challenge test; IADPSG, International Association of the Diabetes and Pregnancy 
Study Groups; NICE, National Institute for Health and Care Excellence; OGTT, oral glucose tolerance test; SIGN, Scottish Intercollegiate 
Guidelines Network; WHO, World Health Organization. 
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studies focuses on GDM, and this Appraisal of Guidelines 
for Research and Evaluation (AGREE) II protocol review 
was undertaken to assess the quality of CPGs and help 
contribute to PAMBAYESIAN’s decision support system.
While AGREE II has received some criticism30 (and 
other tools for evaluating CPGs exist31), it is nevertheless 
an accepted and validated tool for assessing the method-
ological quality of CPGs31; it does not assess the imple-
mentation of the guideline. The AGREE II instrument32 
comprises 23 items arranged in six domains: (1) scope 
and purpose, (2) stakeholder involvement, (3) rigour 
of development, (4) clarity and presentation, (5) appli-
cability and (6) editorial independence. Responses are 
scored on a Likert scale from 1 to 7 (1=strongly disagree, 
7=strongly agree).
One of the motivations for AGREE II in general is to 
address the low rates of adherence to CPGs.33 34 Studies 
have shown the number of health professionals using 
CPGs to be less than one-third.33 34 Of those, around 60% 
failed to review patient records and followed the guideline 
so blindly that they repeated tests that had already been 
conducted, which increases health service wastage.33 34 
The AGREE II study’s primary focus is on the form of 
the guideline: identification of who wrote the guideline, 
conflicts of interest for authors or from funding sources, 
the process for evaluation of evidence and so on. The 
AGREE II committee cite these as primary issues that affect 
the quality and reliability of CPGs and their effect on the 
care delivered in hospitals. The low usage rates observed 
coupled with increased resource wastage conflict with 
the CPGs primary purpose to such degree that issues of 
who wrote or funded its development, and the processes 
they relied on to select and evaluate the evidence may not 
actually be impacting on the quality of care to any signif-
icant degree.33 34 No matter how well a guideline scores 
on the AGREE II protocol, AGREE studies are silent on 
how well the guideline is being applied in practice. Our 
evaluation accordingly does not take account of how well 
CPGs are applied by clinicians in the respective clinical 
environments.
MethODs
We conducted a review of local CPGs addressing GDM 
with quality assessment using the AGREE II instrument.
Guideline selection
Rather than seeking guidelines or guideline reviews 
from the literature, which in many cases only review the 
ideal guidelines of national or non-clinical organisations 
(such as those from medical associations, professional 
colleges, health insurance providers, government health 
departments and so on), we sought a representative selec-
tion of local CPGs developed or required to be used by 
clinicians in western hospitals where training and certi-
fication processes are similar to  those where three of 
our authors trained and practiced. Given that hospitals 
generally do not publish local CPGs in the academic 
literature, it was necessary to perform an internet search 
of government guideline clearinghouse and hospital 
public-access webservers using the search terms hospital, 
CPG, diabetes and pregnancy. The criteria for inclusion 
were that the document (1) was explicitly identified as a 
guideline, (2) was written in English, (3) was produced 
by or for the hospital in a western country, (4) included 
diagnostic criteria and recommendations concerning 
GDM, (5) demonstrated some evaluation or inclusion of 
evidence and (6) was easily accessible over the internet 
to health service consumers. In addition, we ensured (7) 
two CPGs from each country identified. Where more than 
two from any one country met the requirements, the ones 
having the most recent updates were used.
Guideline quality assessment
To increase the reliability of the appraisal, the AGREE 
II protocol user manual recommends each guideline 
be assessed by at least two, but preferably four or more, 
appraisers.32 Adhering to the AGREE II instrument 
protocol, each guideline in this study was independently 
reviewed by five assessors with a range of expertise (a 
neonatal paediatric nurse, a clinical midwifery research 
fellow, a diabetologist, a guideline and learning health 
systems researcher and a learning systems statistician, all 
with knowledge of evidence-based medicine). Reviewers 
did not communicate or confer about the guidelines 
during the review process. Reviewers were provided with 
the guidelines and any supporting documents or related 
publications. Responses were collected using a secure 
online survey tool that exported into an Excel spread-
sheet prepared specifically to report per domain, per 
question and per reviewer. Percentages were calculated in 
Excel for each domain following the AGREE II protocol 
manual algorithm shown in figure 1. Additionally, 
reviewer variance scores were calculated across all scores 
for each question using Excel’s built-in VAR function.
A precedent for categorical, rather than statistical, 
reporting of AGREE II scores has been set by Duda et al35 
and extended by Eady et al.30 In order to make the scores 
more relevant to readers and enable fair comparison, our 
review reports the AGREE II outcomes using the 5-point 
Likert scale described in Eady et al30 as excellent (>80%), 
good (>60%–80%), average (>40%–60%), fair (>20%–
40%) and poor (<20%).
Patient and public involvement
Prior to commencing, the aims of the PAMBAYESIAN 
project including the diabetes component and the AGREE 
II protocol were presented to the North East London 
Diabetes Research Network Lay Panel who have helped 
to inform the research while commenting on the wide 
variation in patient experiences in services provided for 
Figure 1 AGREE II protocol domain scoring algorithm.
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pregnant women. The AGREE II results, once published, 
will be summarised on the PAMBAYESIAN website (web 
address) and by using social media.
results
The internet search resulted in an initial collection of 
CPGs (n=56) from which we selected only those from 
English-speaking western tertiary hospitals—those of the 
UK, New Zealand (NZ), Australia (AUS), Canada (CA) 
and the USA—as shown in figure 2. Those from the USA 
were removed as, while these were sourced from hospital 
facilities, almost all had been produced by health insur-
ance providers and were too limited in the identifica-
tion of evidence or the evaluation process used in their 
production. We could not consider them independent 
or exclude the possibility that they were more concerned 
with limiting clinical test and care modalities that insurers 
would reimburse for rather than standardising best-prac-
tice patient care. A significant body of research identifies 
that good CPGs should be reviewed and updated regu-
larly.36 For this reason, CPGs that were not the current 
version, or had been produced before 2013 were also 
rejected. Two reviewers (BJD and SM) examined titles 
and abstracts to verify eligibility according to the selec-
tion criteria. Both then reviewed the full text to further 
verify eligibility. Given that all CA hospitals we searched 
(n=11) referred us to the same nationally developed CDA 
CPG, the authors allowed its inclusion in order to assess 
the reason for its clinical popularity. The resulting CPG 
collection included two from each of AUS, NZ and the 
UK, and the single CPG from CA. These are shown in 
table 2.
All advising bodies provide guidance on how and when 
screening pregnant women for GDM should ideally occur. 
For some, screening is performed for all women regard-
less of risk factors, while for others, risk stratification 
decides whether women are tested at booking, in early 
second, or during the third trimester. Risks requiring 
early testing include BMI >30, ethnicity, previous history 
of GDM, family history of diabetes and previous macro-
somic baby. All CPGs included a recommendation to 
screen women with risk factors at booking via HbA1c to 
rule out pre-existing diabetes. CPGS based on the NICE 
guideline recommend GDM testing based on clinical risk, 
while those relying on CDA, BPAC, ADIPS and IADPSG 
Figure 2 CPG search and selection. CPG, clinical practice 
guideline.
Table 2 Reviewed guidelines and URLs
Country Author organisation Year Title URL
1 AUS Royal Women’s Hospital 2017 Diabetes mellitus: management of 
gestational diabetes
https://bit.ly/2WyPXqU
2 AUS King Edward Memorial Hospital 2017 Diabetes in pregnancy https://bit.ly/2N1cAeJ
3 NZ Auckland DHB 2013 Diabetes in pregnancy https://bit.ly/2HICO6E
4 NZ Hutt Valley DHB 2015 Diabetes: pre-existing and 
gestational
https://bit.ly/2xBuakU
5 CA Canadian Diabetic Association 2013 Diabetes and pregnancy https://bit.ly/2IdXoud
6 UK Nottingham University Hospital 2016 Guideline on management of 
pregnant women with diabetes
http://bit.do/exsYa
7 UK Barts Health Trust 2015 Diabetes - pregnancy, labour and 
puerperium
http://bit.do/exsXy
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recommend universal testing, or screening then testing, 
for all pregnant women. It should be noted that in certain 
locations within the UK, as a result of ethnic or cultural 
history, risk-based screening results in near universal 
testing in practice.
CPG characteristics
Characteristics of the seven included guidelines are 
presented in table 3. A key issue was poor disclosure of 
the team involved in developing individual CPGs. Three 
were silent on the authoring team, and one described 
the authors only as the ‘Diabetes Team’ without further 
clarification. Another listed the clinical specialties of 
team members without identifying specific individuals. 
Only two (CDA and Barts Health Trust (BHT)) identi-
fied authors and their areas of clinical expertise. Only 
one CPG (Nottingham University Hospital (NUH)) 
identified that patients should be part of the treatment 
team. However, no guideline described consultation with 
service consumers or incorporated a consumer stake-
holder in its development.
The scope of most CPGs in this study was limited. 
While all included differential diagnostic protocols and 
criteria, two were silent regarding antenatal steroid guid-
ance, three provided a recommendation for consider-
ation, and two (ADHB and BHT) provided complete 
guidance for managing diabetes during antenatal corti-
costeroid administration. In our review, two CPGs failed 
to provide guidance as to clinical management during 
labour, three provided limited guidance, and only two 
(KEMH and BHT) provided complete protocols for care 
of the diabetic mother during the labour and birth event. 
One CPG (HVDHB) provided no guidance for post-
natal management and follow-up, while three provided 
limited guidance in the immediate postnatal period. The 
remaining three (NUH, BHT and ADHB) covered the 
immediate postnatal needs of the mother with diabetes, 
as well as providing detailed long - term follow-up .
Appraisal of guidelines and consensus statement
We found that many CPGs did not document their indi-
vidual team’s method of delivering consensus, with some 
(from AUS RWH and UK NUH) relying on the prior 
consensus of an external party whose guiding protocol or 
evidence was used by that CPG’s authors.
Table 4 reports the categorical scores for each domain 
calculated as per the AGREE II protocol.32 The authors 
considered that CPGs with an overall score <70 require 
additional attention and revision to resolve issues causing 
that low score. For example, while both UK CPGs had 
three domains in which the score was ‘above average’, 
issues such as not providing in-text references to identify 
which evidence formed the basis for particular clinical 
decisions, along with limited stakeholder identification 
and involvement, reduced overall scores. While meeting 
several sections of the AGREE II protocol, the NZ HVDHB 
CPG also failed to identify guiding evidence for each deci-
sion, as well as neglecting to identify team members who 
formulated the guideline and any potential conflicts of 
interest they may have had. The AUS KEMH protocol 
provided treatment recommendations and care plans 
but was exceedingly verbose and failed to identify where 
evidence was used or identify any single item of reference 
material.
Average variance provides an indication of the degree 
to which the reviewers gave consistent or agreeing scores 
for each CPG. A score close to 1 indicates little variance, 
which translates to strong agreement. In this study, the 
reviewers agreed strongly with regards to the CPGs that 
received the highest (CA CDA) and lowest (NZ HVDHB) 
AGREE II scores, as shown in table 5. The CPG with the 
greatest variance (AUS KEMH) resulted from one clin-
ical reviewer scoring it higher in domains 1 and 3 (Scope 
and Purpose, and Rigour). That reviewer felt that, even 
though the evidence and references were not provided, 
the text demonstrated rigorous evaluation of evidence to 
arrive at well-devised diagnostic and treatment protocols. 
The remaining reviewers felt that the absence of evidence 
to justify decisions must reduce the overall assessment of 
rigour, as even the most appropriate of clinical decision 
requires justification through supporting evidence.
DIsCussIOn
As judged by the AGREE II protocol, all reviewed local 
hospital guidelines had deficiencies, notably, lack of user 
involvement, assessment of resource implications, listing 
conflicts of interests and lack of external review.
The local CPGs reviewed did not significantly diverge 
from the recommendations of the national or interna-
tional advising bodies on which they were based. NICE 
and BPAC have diagnostic criteria that differ from 
ADIPS, CDA and IADPSG, but their residual recommen-
dations remain consistent. The UK local CPGs broadly 
adhere to NICE recommendations, with refinements in 
one (BHT), which the CPG states is due to a population 
who are predominately classified as high risk. It is noted 
extensively in the literature that tightening the diagnostic 
criteria for GDM will increase the number of women diag-
nosed7; however, it remains unclear if treating the women 
who are outside the current NICE criteria, but within the 
WHO or IADPSG criteria, will result in any reduction in 
targeted complications sufficient to justify the increased 
cost to treat and increased anxiety that disclosure of 
potential pregnancy complications brings.7 11 14 Given 
that an AGREE II protocol study concerns the form and 
structure of the CPG and how it was developed, such 
factors tend to fall outside of the protocol’s remit.
While the Canadian CPG was ranked best overall in 
this review, it lacked in usability in application to daily 
care. The drafting of a practical care pathway would 
be required in order for midwives and obstetricians to 
consistently apply it in clinical practice. The other highly 
ranked CPG, that from NZ ADHB, provided simple but 
clear clinical pathway diagrams, but its use of URL links 
to other hospital documentation meant those sections 
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could only be followed by someone working within the 
hospital. While it provides detailed instructions for post-
natal follow-up, it failed to provide appropriately detailed 
recommendations for fetal surveillance during the 
pregnancy.
At the other end of the spectrum were AUS KEMH 
and NZ HVDHB, which scored equal lowest in this study. 
One was found to be exceedingly verbose (AUS KEMH) 
while the other was found to be altogether too brief in 
its presentation (NZ HVDHB). Much of the AUS KEMH 
guideline concerned inpatient care, with limited support 
provided for care of those women in the community. 
The NZ HVDHB guideline provides easy-to-read careflow 
diagrams for the screening process but failed to provide 
the same for ongoing management. By contrast, those 
local CPGs that scored higher generally provide screening 
and ongoing management protocols as flow diagrams for 
easy review by clinicians.
The UK CPGs were produced to be generally consistent 
with the recommendations of the NICE guidelines. As the 
NICE guidelines are rigorous in their investigation and 
assessment of evidence, the UK guidelines scores were 
not impacted so much by the lack of evidence, but by 
the style and lack of adherence to the format prescribed 
by the AGREE II protocol. We note that such organisa-
tions often produce CPGs based on an internal template 
or style guide, and as such, issues in this area should be 
addressed as a matter for institutional change.
A key finding of our study was that consistent deficien-
cies and inconsistencies permeate guidelines for GDM 
care; a finding that is only possible when reviewing a 
representative sample, and a key motivator for why we 
selected guidelines across a number of developed western 
countries.
All local CPGs in this study provided glycaemic control 
targets at levels equal to or better than their respective 
diagnostic criteria for GDM. Similarly, all CPGs included 
guidance on initiation of medication (metformin and/
or insulin) if diet modification and exercise failed to 
achieve glycaemic control. One CPG (AUS KEMH) 
provided extensive guidance on education and adminis-
tration of insulin for the patient. All CPGs recommended 
the transfer of GDM patients requiring medication into 
a high-risk or multidisciplinary care team, with provision 
for diet-controlled women to remain in their community 
teams with secondary care oversight. All CPGs encour-
aged community, primary care models for diet-controlled 
GDM and allowed the pregnancy to continue to 41 weeks’ 
gestation before recommending elective delivery. This 
reduces the number of interventions for women with 
well-controlled GDM. All CPGs agreed on earlier elective 
delivery (from 38 to 39 weeks’ gestation), if the woman 
required medication to achieve glycaemic control.
This study found that fetal surveillance recommen-
dations varied markedly: CDA contained no advice on 
ultrasound or fetal condition monitoring during preg-
nancy; ADHB stated that GDM in itself was not a reason 
for increased fetal surveillance and accordingly made 
no specific recommendations; most other CPGs recom-
mended some form of ultrasound monitoring if the 
woman required medication for glycaemic control. It 
should be noted that none of the seven advising bodies 
Table 4 Summary of adjusted scores using the AGREE II reporting checklist
Guideline
Scope and 
purpose
Stakeholder 
involvement Rigour Clarity Applicability
Editorial 
independence
No. of domains 
above average
Overall 
AGREE II 
score
1 AUS RWH Excellent Fair Fair Good Average Fair 2 66.6
2 AUS KEMH Average Average Fair Good Average Average 1 50
3 NZ ADHB Excellent Average Average Good Average Average 2 83.3
4 NZ HVDHB Excellent Average Average Good Fair Average 2 50
5 CA CDA Excellent Good Good Excellent Good Average 5 91.6
6 UK NUH Excellent Good Average Good Average Fair 3 66.6
7 UK BHT Excellent Good Average Good Average Average 3 58.3
ADHB, Auckland DHB; AGREE II, Appraisal of Guidelines for Research and Evaluation II; BHT, Barts Health Trust; CDA, Canadian Diabetic 
Association; HVDHB, Hutt Valley DHB; KEMH, King Edward Memorial Hospital; NUH, Nottingham University Hospital; RWH, Royal Women’s 
Hospital. 
Table 5 Average variance of scores across all AGREE II 
domains
Guideline Average variance
1 AUS RWH 3.07
2 AUS KEMH 3.69
3 NZ ADHB 2.03
4 NZ HVDHB 1.65
5 CA CDA 1.08
6 UK NUH 2.09
7 UK BHT 2.23
ADHB, Auckland DHB; AGREE II, Appraisal of Guidelines for 
Research and Evaluation II; BHT, Barts Health Trust; CDA, 
Canadian Diabetic Association; HVDHB, Hutt Valley DHB; KEMH, 
King Edward Memorial Hospital; NUH, Nottingham University 
Hospital; RWH, Royal Women’s Hospital. 
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listed in table 1 included recommendations for fetal 
surveillance in GDM pregnancies in their consensus 
statements.
In summary, this review analysed seven current hospital 
CPGs addressing the diagnosis and management of GDM 
and confirmed significant variation on the quality of the 
local guidelines. Only two CPGs (CA CDA and NZ ADHB) 
were considered by the authors to be of acceptable quality 
when assessed using the AGREE II criteria, demonstrated 
by achieving a score >70. Two received a score of 50 (AUS 
KEMH and NZ HVDHB) and were regarded as flawed 
by the authors. For the remaining three (AUS RWH, UK 
NUH and UK BHT), minimal work would be required 
to improve the template and presentation approach in 
order to meet AGREE II standards, as no significant issue 
could be raised with their clinical recommendations 
which adhered to suitable advising body guidelines.
There are a number of limitations to this study. Only 
two selected CPGs were selected from tertiary hospitals 
and from only three English-speaking countries; further-
more, CPGs before 2013 were not considered, even 
though in many settings they are still used in current clin-
ical practice. Nonetheless, the range of AGREE II scores 
suggests that we captured the range of available guide-
lines thus confirming that there is wide variation in local 
guidelines. While the AGREE II protocol sets a minimum 
of two reviewers, but preferably more for a successful 
protocol review, our study used five. Given the range of 
qualifications and experience of the reviewers in this 
study, we believe this significantly adds to the robustness 
of the results. We restricted our evaluation to GDM and 
did not include the management of pre-existing diabetes; 
this narrowed down the available guidelines for review. 
An alternate approach would have been to evaluate all the 
international guidelines. However, in a tertiary setting, 
they are interpreted locally leading to the guidelines used 
in the local clinical setting, which was the subject of our 
review. Finally, the AGREE II protocol does not assess the 
evidence base of the clinical content of the guideline, or 
its implementation. Thus, a guideline reviewed may score 
highly, independent of the local or national adaptation 
of the international guideline but does not indicate the 
clinical quality of the decision making or the evidence or 
how it was adapted for local needs.
COnClusIOn
Good quality local CPGs provide complete care for the 
identified patient cohort during the identified health 
incident (in this case, pregnant women with GDM). 
Authors of CPGs should ensure that the evidence relied 
on to guide clinical decisions within the CPG is directly 
referenced so that users can be assured of the rigour 
and appropriateness of the recommendation. This was 
a key area lacking in almost all of the CPGs reviewed. 
CPGs should not omit steps relevant to the care of their 
patient cohort. Nor should they require additional time 
and effort on the part of clinicians to seek out sections 
of other CPGs or clinical artefacts (such as a separate 
labour and birth guideline with a section dealing with 
delivery of the diabetic mother). Although each of the 
CPGs reviewed in this study was found to be a complete 
guideline, the degree of detail and justification provided 
in some requires attention.
Future development of local CPGs should include 
a clear listing of those who have undertaken develop-
ment of the guideline, user involvement, an assessment 
of resource implications, a listing of conflicts of interests 
and external review.
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